



## Helixmith Co., Ltd.

CEO  
Sunyoung Kim

Location  
21, Magokjungang 8-ro 7-gil,  
Gangseo-gu, Seoul 07794,  
Korea

Specialty  
plasmid DNA-based gene  
therapy

Tel / Fax / E-mail  
T. 82-2-2102-7100  
F. 82-2-887-0011  
E. [contact@helixmith.com](mailto:contact@helixmith.com)

Founded in 1996, Helixmith has been dedicated to research in gene therapy for over 20 years. Led by Sunyoung Kim and his lab in Seoul National University, the Helixmith team has developed an extremely powerful gene expression system and has tested it in various therapeutic areas. The company is currently headquartered in Seoul, Korea; our clinical development and manufacturing activities are based in San Diego, California in the US. In particular, we co-own a cGMP-ready DNA production facility, Genopis, Inc., an affiliated CDMO in San Diego. Genopis serves both Helixmith and external customers in need of DNA.

### Main Products

Product	Target Disease	Technology	Country	Development Stage
VM202	Diabetic peripheral neuropathy	Gene therapy	US	Phase 3 / FDA RMAT
	Diabetic foot ulcer	Gene therapy	US	Phase 3
	Ischemic heart disease	Gene therapy	Korea	Phase 2
Orphan Drug	Amyotrophic lateral sclerosis	Gene therapy	US	Phase 2 / FDA Fast Track
VM206	Breast cancer	DNA vaccine	Korea	Phase 2

### R&D Pipeline

